Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer
作者:Yong Wu、Jianbei Xi、Yue Li、Zheng Li、Yong Zhang、JianFei Wang、Guo-Huang Fan
DOI:10.1021/acs.jmedchem.3c00030
日期:——
described a potent and selectiveCCR8antagonist (compound 1, IPG7236) as the first small molecule to advance to the clinical stage. IPG7236 demonstrated an anti-cancer effect via modulating Treg and cytotoxic T (CD8+ T) cells. IPG7236 alone or in combination with PD-1 antibody exhibited significant tumor suppression effects in the mouse xenograft model of human breast cancer. IPG7236 is a promising
最近,越来越多的证据表明 CC 趋化因子受体 8 (CCR8) 在调节肿瘤微环境中调节性 T (T reg ) 细胞的募集和免疫抑制功能方面发挥着重要作用。因此,开发特定的 CCR8 拮抗剂是一种潜在的抗癌治疗策略。尽管有一些小分子被报道为 CCR8 拮抗剂,但没有一个进入临床阶段。在此,我们描述了一种有效的选择性 CCR8 拮抗剂(化合物1,IPG7236)作为第一个进入临床阶段的小分子。IPG7236 通过调节 T reg和细胞毒性 T (CD8 +T) 细胞。IPG7236 单独或与 PD-1 抗体联合在人乳腺癌小鼠异种移植模型中表现出显着的肿瘤抑制作用。IPG7236 是一种有前途的临床候选药物,靶向 CCR8,具有出色的体外ADMET 特性、药代动力学、安全性和体内功效。
Modulators of indoleamine 2,3-dioxygenase
申请人:GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:US10927078B2
公开(公告)日:2021-02-23
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
本文提供了式 I 的 IDO 抑制剂化合物及其药学上可接受的盐、它们的药物组合物、它们的制备方法以及它们用于预防和/或治疗疾病的方法。
MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
申请人:GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:US20200165201A1
公开(公告)日:2020-05-28
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
[EN] MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE<br/>[FR] MODULATEURS D'INDOLAMINE 2,3-DIOXYGÉNASE
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2019003141A1
公开(公告)日:2019-01-03
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. Formula I